跳至主要内容
临床试验/jRCTs061180034
jRCTs061180034已完成不适用

A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer (A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer)

未提供0 个研究点目标入组 12 人开始时间: 2016年5月17日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
12
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Colorectal cancer proven by histology or imaging (CT or MRI)
  • Patients with HLA-A*2402
  • Standard treatment failure colorectal cancer
  • Performance Status (PS); 0-2, Eastern Cooperative
  • Oncology Group (ECOG)
  • Preserved organ functions (number of WBCs more than
  • 2.0x103/mm3; % of lymphocyte >=15; number of platelets
  • >=7.5x103/mm3; hemoglobin >=8.0 g/ dl; creatinine <=2.5
  • times of upper normal limit)
  • 7.Patients provided written, informed consent to participate

排除标准

  • The exclusion criteria were, double cancer, pneumonitis, severe allergy, severe infection, neurological disturbance, uncontrolled general diseases, heart diseases, general steroid treatment, or any prior therapies using same agents of this study.

结局指标

主要结局

-

safety

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验

CpG trial (CpG trial) | 临床试验